---
title: "LEPU BIO-B has entered into an exclusive licensing agreement for the innovative ADC MRG007"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/225753665.md"
description: "LEPU BIO-B has signed an exclusive licensing agreement with ArriVent Biopharma, Inc., authorizing the latter to develop and commercialize the antibody-drug conjugate MRG007 globally (excluding Greater China). LEPU BIO-B will receive an upfront payment of $47 million and milestone payments, and will also receive royalties in the high single digits to low double digits, with a maximum of $1.16 billion in development, registration, and sales milestone payments"
datetime: "2025-01-22T00:13:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225753665.md)
  - [en](https://longbridge.com/en/news/225753665.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225753665.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/225753665.md) | [繁體中文](https://longbridge.com/zh-HK/news/225753665.md)


# LEPU BIO-B has entered into an exclusive licensing agreement for the innovative ADC MRG007

According to the announcement from LEPU BIO-B (02157), on January 22, 2025, the company entered into an exclusive licensing agreement with ArriVent Biopharma, Inc. (which is listed on the NASDAQ Global Market under the stock code: AVBP). Under this agreement, the company grants ArriVent an exclusive license to develop and commercialize the group's innovative antibody-drug conjugate MRG007 globally (excluding Greater China).

According to the licensing agreement, the company grants ArriVent: (i) an exclusive license for the intellectual property rights related to MRG007 owned or controlled by the group to develop, manufacture, and commercialize any products containing MRG007 in the licensed territory; and (ii) a non-exclusive license for the intellectual property rights related to MRG007 controlled by the group to develop, manufacture, and commercialize any products containing MRG007 for tumor treatment in the licensed territory.

Subject to the terms and conditions of the licensing agreement, ArriVent is authorized to develop, manufacture, and commercialize MRG007 under the exclusive license in the licensed territory. Meanwhile, the company will receive a one-time upfront payment and recent milestone payments totaling $47 million, as well as milestone payments of up to $1.16 billion for development, registration, and sales, along with a tiered royalty of high single digits to low double digits on the net sales of MRG007 in the licensed territory

### 相关股票

- [LEPU BIO-B (02157.HK)](https://longbridge.com/zh-CN/quote/02157.HK.md)

## 相关资讯与研究

- [Massive news for Intel stock investors](https://longbridge.com/zh-CN/news/281671701.md)
- [10:00 ETSanyou Milestone | Recognized as a "Shanghai Municipal Enterprise Technology Center," Further Validating for Innovation Excellence](https://longbridge.com/zh-CN/news/281035304.md)
- [CATL's controlling shareholder to donate some A-shares](https://longbridge.com/zh-CN/news/281197776.md)
- [Fenbi Appoints Chairman Zhang Xiaolong as New Authorized Representative](https://longbridge.com/zh-CN/news/281528628.md)
- [Henlius Wins Key EMA Backing for Cancer Drug Serplulimab in Europe](https://longbridge.com/zh-CN/news/280997570.md)